Payment overview · 2025
General Payments
$1,314.67
65 reported records · 16 companies
Healthcare provider profile · identity verified
Barry J Mccleney, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGVILLE, AL · NPI 1467514687
Verified facts
What the public records show
CMS Open Payments records show Barry J Mccleney, MD received $1,314.67 in general payments during 2025 across 65 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Nuzyra, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Paratek Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUZYRA as an associated drug or biological on 24089 records involving 10216 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuzyra by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $302.52 | 23.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $226.79 | 17.2% | 12 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $190.13 | 14.5% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $112.02 | 8.5% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.15 | 6.9% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.72 | 6.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.15 | 5.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.65 | 3.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.15 | 3.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.69 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.61 | 2.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.32 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.39 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.26 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,314.67 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $346.17 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $226.79 | 12 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $190.13 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.72 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.15 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.75 | 3 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $56.42 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.03 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.40 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.32 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
| NUZYRA nuzyra |
2025 | Nuzyra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 150 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
150 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| Paratek Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | NUZYRA open payments reported associated product |
CMS Open Payments — General Payments 24089 supporting records · 10216 recipient NPIs · example record 1181734338 |
Nuzyra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 689 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 678 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 196 |
| Pantoprazole Sodium | Pantoprazole Sodium | 676 | 164 |
| Lisinopril | Lisinopril | 647 | 184 |
| Gabapentin | Gabapentin | 429 | 85 |
| Omeprazole | Omeprazole | 384 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 375 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 370 | 113 |
| Cefdinir | Cefdinir | 350 | 239 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 321 | 89 |
| Carvedilol | Carvedilol | 303 | 71 |
| Furosemide | Furosemide | 264 | 78 |
| Metformin Hcl Er | Metformin Hcl | 256 | 68 |
| Metformin Hcl | Metformin Hcl | 252 | 73 |
| Trazodone Hcl | Trazodone Hcl | 247 | 55 |
| Alendronate Sodium | Alendronate Sodium | 236 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 56 |
| Losartan Potassium | Losartan Potassium | 228 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 221 | 33 |
| Montelukast Sodium | Montelukast Sodium | 204 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 188 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 49 |
| Eliquis | Apixaban | 180 | 39 |
| Buspirone Hcl | Buspirone Hcl | 174 | 46 |
| Potassium Chloride | Potassium Chloride | 156 | 43 |
| Methylprednisolone | Methylprednisolone | 154 | 124 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 152 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 45 |
| Ozempic | Semaglutide | 150 | 31 |
| Levofloxacin | Levofloxacin | 149 | 97 |
| Simvastatin | Simvastatin | 149 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 49 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 143 | 38 |
| Ezetimibe | Ezetimibe | 140 | 35 |
| Mounjaro | Tirzepatide | 140 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 33 |
| Tramadol Hcl | Tramadol Hcl | 132 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 39 |
| Clonazepam | Clonazepam | 126 | 23 |
| Clonidine Hcl | Clonidine Hcl | 122 | 28 |
| Famotidine | Famotidine | 122 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 119 | 89 |
| Glimepiride | Glimepiride | 118 | 31 |
| Meloxicam | Meloxicam | 116 | 41 |
| Spironolactone | Spironolactone | 113 | 30 |
| Allopurinol | Allopurinol | 112 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 26 |
| Acarbose | Acarbose | 101 | 19 |
| Benazepril Hcl | Benazepril Hcl | 100 | 29 |
| Atenolol | Atenolol | 97 | 28 |
| Azithromycin | Azithromycin | 97 | 81 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 97 | 28 |
| Jardiance | Empagliflozin | 96 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 25 |
| Ibuprofen | Ibuprofen | 93 | 29 |
| Methocarbamol | Methocarbamol | 90 | 29 |
| Sertraline Hcl | Sertraline Hcl | 88 | 31 |
| Pregabalin | Pregabalin | 85 | 16 |
| Promethazine Hcl | Promethazine Hcl | 83 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 77 | 14 |
| Farxiga | Dapagliflozin Propanediol | 76 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 21 |
| Ondansetron Odt | Ondansetron | 74 | 27 |
| Lorazepam | Lorazepam | 73 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 17 |
| Bupropion Xl | Bupropion Hcl | 69 | 16 |
| Estradiol | Estradiol | 67 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 66 | 19 |
| Mupirocin | Mupirocin | 65 | 35 |
| Baclofen | Baclofen | 64 | 19 |
| Fluconazole | Fluconazole | 64 | 35 |
| Meclizine Hcl | Meclizine Hcl | 64 | 26 |
| Ketoconazole | Ketoconazole | 63 | 34 |
| Alprazolam | Alprazolam | 62 | suppressed |
| Prednisone | Prednisone | 58 | 13 |
| Lansoprazole | Lansoprazole | 57 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 39 |
| Trulicity | Dulaglutide | 56 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 15 |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 54 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 13 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 12 |
| Celecoxib | Celecoxib | 47 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 12 |
| Linzess | Linaclotide | 47 | 11 |
| Hydrocortisone | Hydrocortisone | 46 | 15 |
| Dutasteride | Dutasteride | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 12 |
| Lovastatin | Lovastatin | 41 | 13 |
| Sucralfate | Sucralfate | 41 | 20 |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Valsartan | Valsartan | 39 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 12 |
| Myrbetriq | Mirabegron | 37 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 12 |
| Amoxicillin | Amoxicillin | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 13 |
| Nystatin | Nystatin | 35 | 17 |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 32 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Bumetanide | Bumetanide | 27 | 11 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 11 |
| Folic Acid | Folic Acid | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Temazepam | Temazepam | 16 | suppressed |
| Terconazole | Terconazole | 16 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nuzyra | Omadacycline Tosylate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,314.67 · 65 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XHANCE, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error